Novel SA-53 MDM2 Inhibitor Therapy Has Potential to be a Breakthrough in Genetically Targeted Cancer Treatment (CLEVELAND, OH) – Steady progress for Lamassu Biotech’s potentially transformative cancer treatment. The private, pioneering...
Tag: SA53
04/14/2026
Crain’s Cleveland Business: Former FDA leader appointed to Lamassu Biotech board of directors
A former executive at the U.S. Food and Drug Administration has been named to a Cleveland biotech company’s board of directors. Dr. Stephen Hahn, the 24th Commissioner of Food and...
Novel SA53 MDM2 Inhibitor Therapy Has Potential to be a Breakthrough in Genetically-Targeted Cancer Treatment (CLEVELAND, OH) – Lamassu Biotech, a clinical-stage pharmaceutical company, today announced a significant clinical milestone...